<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00059917</url>
  </required_header>
  <id_info>
    <org_study_id>CTI-PGC101</org_study_id>
    <secondary_id>MSKCC-03002</secondary_id>
    <secondary_id>CDR0000298987</secondary_id>
    <nct_id>NCT00059917</nct_id>
  </id_info>
  <brief_title>Polyglutamate Camptothecin in Treating Patients With Advanced Cancer</brief_title>
  <official_title>Phase I Study of CT-2106 in Patients With Advanced Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as polyglutamate camptothecin may be able to&#xD;
      deliver the drug directly to tumor cells while leaving normal cells undamaged.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of polyglutamate camptothecin in treating&#xD;
      patients who have advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of polyglutamate camptothecin (CT-2106) in patients&#xD;
           with advanced malignancies.&#xD;
&#xD;
        -  Determine the tolerability of this drug in these patients.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.&#xD;
&#xD;
        -  Determine the disease response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive polyglutamate camptothecin (CT-2106) IV over 10 minutes on day 1. Courses&#xD;
      repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      receive 2 additional courses beyond confirmation of complete response.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of CT-2106 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed at 3 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-48 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>polyglutamate camptothecin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced malignancy&#xD;
&#xD;
          -  No active brain metastases (as indicated by clinical symptoms, cerebral edema, or&#xD;
             progressive tumor growth) that have been unstable for at least 8 weeks&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times ULN (5 times ULN if liver metastases are&#xD;
             present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No history of hemorrhagic cystitis&#xD;
&#xD;
          -  No history of microscopic hematuria associated with drug therapy or radiotherapy or of&#xD;
             unknown origin&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No significant cardiac disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to comply with study schedule and assessments&#xD;
&#xD;
          -  No other significant nonmalignant systemic disease&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other condition that would in the investigator's opinion make the patient an&#xD;
             inappropriate study candidate&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior definitive radiotherapy (except for palliative reasons&#xD;
             to sites of nonmeasurable disease, in patients with measurable disease at baseline)&#xD;
&#xD;
          -  Concurrent palliative radiotherapy allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major thoracic or abdominal surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy (except alopecia or stable grade 1 neuropathy)&#xD;
&#xD;
          -  More than 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No prior myeloablative therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob Dupont, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McNamara MV, Doroshow JH, Dupont J, et al.: Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. [Abstract] J Clin Oncol 22 (Suppl 14): A-2073, 145s, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Springett GM, Takimoto C, McNamara M, et al.: Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. [Abstract] J Clin Oncol 22 (Suppl 14): A-3127, 226s, 2004.</citation>
  </results_reference>
  <verification_date>April 2005</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

